이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

이식에 적합하지 않은 새로 진단된 골수종 환자의 두 가지 치료법을 비교하는 시험 (KRdvsRd)

2026년 9월 17일 업데이트: Fondazione EMN Italy Onlus

자가 줄기 세포 이식에 적합하지 않은 새로 진단된 골수종 환자에서 카르필조밉 - 레날리드마이드 - 덱사메타손(KRd) 대 레날리도미 - 덱사메타손(Rd): 무작위 3상 시험

The combination of lenalidomide plus low-dose dexamethasone (Rd) is considered the new standard for elderly newly diagnosed multiple myeloma (NDMM) patients. The combination carfilzomib plus lenalidomide-dexamethasone (KRd) in relapsed-refractory MM patients improved the progression-free survival (PFS) of approximately 1 year compared to standard Rd treatment. In a small phase 2 trial (23 pts) the KRd combination in elderly NDMM pts showed a complete response (CR) rate of 79% and a PFS at 3 years of 80%. Cardiovascular adverse events are the most limiting toxicities, especially in elderly patients.

연구 개요

상세 설명

This protocol is a randomized, multicenter study designed to determine the MRD negativity and the PFS of KRd treatment regimen.

Patients will be randomized in a 1:1 ratio to receive carfilzomib-lenalidomide-dexamethasone (KRd - Arm A) or lenalidomide-dexamethasone (Rd - Arm B).

Patients will be stratified basing on international staging system (ISS) and fitness status using a web-based procedure completely concealed to study participants.

All consecutive patients ≥ 65 years with newly diagnosed MM will be enrolled in a large randomized study during a period of 24 months.

Patients will be treated until disease progression or intolerance to the therapy. The only exception is for patients enrolled in KRd arm who achieve at least a VGPR during the first year of treatment and in sustained MRD negativity (MRD negative at least at 10-5 after one and two years of therapy): these patients will stop carfilzomib administration after 2 years, whereas treatment with lenalidomide and dexamethasone will be continued.

연구 유형

중재적

등록 (실제)

84

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Alessandria, 이탈리아
        • AO "SS. Antonio e Biagio"
      • Ancona, 이탈리아
        • AOU Ospedali Riuniti Umberto I
      • Ascoli Piceno, 이탈리아
        • Ospedale Mazzoni
      • Bari, 이탈리아
        • Policlinico di Bari
      • Bergamo, 이탈리아
        • Ospedali Riuniti
      • Bolzano, 이탈리아
        • Azienda Sanitaria di Bolzano - Ospedale Lorenz B:Ohler
      • Brescia, 이탈리아
        • A.O. Spedali Civili di Brescia
      • Cagliari, 이탈리아
        • Ospedale "A. Businco"
      • Candiolo, 이탈리아
        • Istituto per la Cura e la RIcerca del Cancro di Candiolo
      • Cuneo, 이탈리아
        • Ospedale Civico S. Croce e Carle
      • Florence, 이탈리아
        • AOU Careggi
      • Meldola, 이탈리아
        • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.)
      • Messina, 이탈리아
        • Azienda Ospedaliera Papardo
      • Messina, 이탈리아
        • Policlinico Universitario di Messina
      • Milan, 이탈리아
        • ASST Grande Ospedale Metropolitano Niguarda
      • Milan, 이탈리아
        • Istituto Europeo Oncologico
      • Milan, 이탈리아
        • Istituto Nazionale Tumori
      • Milan, 이탈리아
        • Ospedale Maggiore Policlinico di Milano
      • Naples, 이탈리아
        • Università Federico II-Policlinico
      • Novara, 이탈리아
        • Ospedale Maggiore
      • Orbassano, 이탈리아
        • AO San Luigi Gonzaga
      • Padova, 이탈리아
        • AO di Padova
      • Palermo, 이탈리아
        • AO Cervello
      • Perugia, 이탈리아
        • Ospedale S. Maria della Misericordia
      • Ravenna, 이탈리아
        • Ospedale Santa Maria delle Croci
      • Reggio Calabria, 이탈리아
        • AO Bianchi Melacrino Morelli
      • Reggio Emilia, 이탈리아
        • Ausl-Irccs
      • Rimini, 이탈리아
        • Ospedale Infermi
      • Rionero in Vulture, 이탈리아
        • Ospedale Oncologico Regionale
      • Roma, 이탈리아
        • Ospedale San Camillo Forlanini
      • Roma, 이탈리아
        • Policlinico Umberto I - Università La Sapienza
      • Roma, 이탈리아
        • ASL Roma 1
      • Roma, 이탈리아
        • Azienda Ospedaliera Universitaria Policlinico Tor Vergata
      • Roma, 이탈리아
        • Ospedale S. Eugenio - Università Tor Vergata
      • Rozzano, 이탈리아
        • Istituto Clinico Humanitas
      • San Giovanni Rotondo, 이탈리아
        • IRCCS Ospedale Casa Sollievo della Sofferenza
      • Terni, 이탈리아
        • AO S. Maria
      • Torino, 이탈리아
        • AOU Città della Salute e della Scienza di Torino - PO Molinette - Ematologia U
      • Torino, 이탈리아
        • AOU Città della Salute e della Scienza di Torino - PO Molinette
      • Udine, 이탈리아
        • Policlinico Universitario di Udine

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

65년 이상 (고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Newly diagnosed symptomatic MM based on either standard CRAB criteria (at least 10% of clonal bone marrow plasma cells plus CRAB defined as the onset of any of the following clinical symptoms: hypercalcemia, renal failure, anemia and bone lesions) or at least 10% of bone marrow plasma cells plus the presence of at least one of the following biomarkers of malignancy:

    • 60% or greater clonal plasma cells on bone marrow examination;
    • Serum involved/uninvolved free light chain (FLC) ratio of 100 or greater;
    • More than one focal lesion on magnetic resonance imaging (MRI) that is at least 5 mm or greater in size.
  • Patient not eligible for ASCT (age ≥ 65 years or abnormal cardiac, pulmonary and liver function).

  • Patient defined as fit or intermediate according to the IMWG (International Myeloma Working Group) frailty score

  • Patient has given voluntary written informed consent.

  • Patient is able to be compliant with hospital visits and procedures required per protocol.

  • Patient agrees to use acceptable methods for contraception.

  • Patient has measurable disease according to IMWG criteria.

  • Patient has ECOG (Eastern Cooperative Oncology Group) performance status < 3.

  • Pre-treatment clinical laboratory values within 30 days before randomization:

    • Platelet count ≥50 x 109/L (≥30 x 109 /L if myeloma involvement in the bone marrow is > 50%)
    • Absolute neutrophil count (ANC) ≥ 1 x 109/L without the use of growth factors
    • Corrected serum calcium ≤14 mg/dL (3.5 mmol/L)
    • Alanine transaminase (ALT): ≤ 3 x the ULN
    • Total bilirubin: ≤ 2 x the ULN
    • Calculated or measured creatinine clearance: ≥ 30 mL/minute.
  • LVEF≥ 40%: 2-D transthoracic echocardiogram (ECHO) is the preferred method of evaluation; multigated Acquisition Scan (MUGA) is acceptable if ECHO is not available

  • Pre-treatment blood pressure value < 140/90 mmHg even with adequate therapy: 24 hours blood pressure monitoring is the preferred method of evaluation; blood pressure diary at home for 2 weeks is acceptable.

  • Females of childbearing potential (FBCP) comply with the conditions of the Pregnancy Prevention Plan, including confirmation that she has an adequate level of understanding.

  • FBCP must follow the Pregnancy Prevention Plan and use a highly effective and an additional barrier contraception method simultaneously for 4 weeks before starting therapy, during treatment and dose interruptions and for at least 30 days after the last dose of study drugs*

  • Males must use an effective barrier method of contraception if sexually active with FCBP during the treatment and for at least 90 days after the last administration of study drug/s. Male subjects must agree to refrain from sperm donation for at least 90 days after the last dose of carfilzomib.

Exclusion Criteria:

  • Serious medical condition, laboratory abnormality or psychiatric illness that prevented the subject from the screening or place the subject at unacceptable risk.

  • Patient defined as frail according to the IMWG frailty score.

  • Previous treatment with anti-myeloma therapy (does not include radiotherapy, bisphosphonates, or a single short course of steroid < to the equivalent of dexamethasone 40 mg/day for 4 days).

  • Pregnant or lactating females.

  • Presence of:

    • Clinical active infectious hepatitis type A, B, C or HIV
    • Acute active infection requiring antibiotics or infiltrative pulmonary disease
    • Pulmonary hypertension and interstitial lung disease
    • Uncontrolled arrhythmias or history of QT prolongation
    • Myocardial infarction or unstable angina ≤ 6 months or other clinically significant heart disease
    • Peripheral neuropathy or neuropathic pain grade 2 or higher, as defined by National Cancer Institute Common Toxicity Criteria (NCI CTC) 5.0 (Appendix A)
    • Uncontrolled hypertension defined as persistent hypertension (>140/90 mmHg) regardless treatment with 3 drugs, including a diuretic.
  • Contraindication to any of the required drugs or supportive treatments and hypersensitivity to any excipient of the study drugs.

  • Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib).

  • Invasive malignancy within the past 3 years.

  • Administration of any experimental drug within 4 weeks prior the baseline or within 5 drug half-lives.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: KRd (Experimental Arm)

Carfilzomib (K):

  • 20 mg/m2 IV on day 1 of cycle 1;
  • 56 mg/m2 IV on days 8 and 15 in cycle 1;
  • 56 mg/m2 IV on days 1, 8 and 15 in cycles 2-12;
  • 56 mg/m2 on days 1 and 15 from cycle 13 and onwards.

Lenalidomide (R):

- 25 mg orally on days 1-21 of each cycle.

Dexamethasone (d):

- 40 mg orally on days 1, 8, 15 and 22 of each cycle. Each cycle is a 28-day cycle.

Until PD or intolerance. Only patients that achieve at least a VGPR within the first year of treatment and in sustained MRD negativity (MRD negative at least at 10-5 after 1 and 2 years of therapy) will stop carfilzomib after 2 years of treatment, and will continue with lenalidomide and dexamethasone administration.

  • 20 mg/m2 IV on day 1 of cycle 1 enhanced to 56 mg/m2 on days 8, and 15 of cycle 1;
  • 56 mg/m2 IV on days 1, 8 and 15 in cycles 2-12;
  • 56 mg/m2 IV on days 1 and 15 from cycle 13 and onwards.
다른 이름들:
  • 키프롤리스

- 25 mg orally on days 1-21 of each cycle.

다른 이름들:
  • 레블리미드

- 40 mg orally on days 1, 8, 15 and 22 of each cycle. Each cycle is to be repeated every 28 days. Patients that achieve at least a VGPR within the first year of study treatment and in sustained MRD negativity (MRD negative at least at 10-5 after 1 and 2 years of therapy) will stop carfilzomib administration after 2 years and will continue with lenalidomide and dexamethasone treatment until disease progression or intolerance to the therapy. Other patients will continue carfilzomib administration until disease progression or intolerance.

For patients >75 years of age, the dose of dexamethasone is 20 mg/day on Days 1, 8, 15 and 22 of each treatment cycle.

활성 비교기: Rd (Control Arm)

Lenalidomide (R):

-25 mg orally on days 1-21 of each cycle.

Dexamethasone (d):

-40 mg orally on days 1, 8, 15 and 22 of each cycle. Each cycle is a 28-day cycles.

Until PD or intolerance.

- 25 mg orally on days 1-21 of each cycle.

다른 이름들:
  • 레블리미드

- 40 mg orally on days 1, 8, 15 and 22 of each cycle. Each cycle is to be repeated every 28 days. Patients that achieve at least a VGPR within the first year of study treatment and in sustained MRD negativity (MRD negative at least at 10-5 after 1 and 2 years of therapy) will stop carfilzomib administration after 2 years and will continue with lenalidomide and dexamethasone treatment until disease progression or intolerance to the therapy. Other patients will continue carfilzomib administration until disease progression or intolerance.

For patients >75 years of age, the dose of dexamethasone is 20 mg/day on Days 1, 8, 15 and 22 of each treatment cycle.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Minimal residual disease (MRD)
기간: 5 years

1. Minimal residual disease (MRD): unit of measure is not applicable, MRD is expressed as a pure number

5 years
Progression-free survival (PFS)
기간: 5 years

2. Progression-free survival (PFS): unit of measure is not applicable, PFS is expressed as a pure number

5 years

2차 결과 측정

결과 측정
측정값 설명
기간
Rate of drug reduction or drug discontinuation
기간: 5 years

Incidence of dose reduction and drug discontinuation in both treatment arms.

5 years
Cardiovascular assessment
기간: 5 years

Benefit of proper cardiovascular baseline assessment and monitoring during treatment in both treatment arms:to mitigate major cardiovascular adverse event incidence, to prolong duration of treatment, to improve efficacy.

5 years
Rate of dose reduction, drug discontinuation and toxicities
기간: 5 years

Safety as rate of dose reduction, drug discontinuation and toxicities

5 years
Response rate
기간: 5 years

Response rate will include complete response (CR), very good partial response (VGPR) and partial response (PR) using the International Response Criteria. Responders are defined as subjects with at least a PR.

5 years
Progression-free survival 2 (PFS2)
기간: 5 years

Time from randomization to objective tumor progression on next-line treatment or death from any cause.

5 years
Time to progression (TTP)
기간: 5 years

Time to progression will be measured from the date of randomization to the date of first observation of PD, or deaths related to PD.

5 years
Duration of response (DOR)
기간: 5 years

Time between first documentation of response and PD. Responders without disease progression will be censored either at the time of lost to FU, at the time of death due to other cause than PD, or at the end of the study.

5 years
Overall survival (OS)
기간: 5 years

Time between randomization and death. Subjects who die will be censored at time of death as an event, regardless cause of death.

5 years
Time to next therapy (TNT)
기간: 5 years

Time to next therapy will be measured from the date of randomization to the date of next anti-myeloma therapy. Death due to any cause before starting therapy will be considered an event.

5 years
MRD negativity
기간: 5 years

Correlation between MRD negativity and PFS, PFS2, TTP, TNT and OS

5 years
Prognostic factors
기간: 5 years

The following outcomes will be analysed in subgroups with different prognostic factors:

  • Progression-free survival (PFS),
  • Time to second disease progression (PFS2),
  • Time to progression (TTP),
  • Time to next therapy (TNT ),
  • Overall survival (OS)
5 years

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Sara Bringhen, A.O.U. Città della Salute e della Scienza

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2019년 7월 1일

기본 완료 (추정된)

2027년 9월 1일

연구 완료 (추정된)

2027년 9월 1일

연구 등록 날짜

최초 제출

2019년 7월 2일

QC 기준을 충족하는 최초 제출

2019년 9월 17일

처음 게시됨 (실제)

2019년 9월 19일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 21일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 17일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다